Comparison of Effect of Bromocriptine mesylate and Pioglitazone in uncontrolled type 2 Diabetic Patients
- Conditions
- Health Condition 1: E119- Type 2 diabetes mellitus without complicationsHealth Condition 2: null- Uncontrolled Type 2 Diabetes
- Registration Number
- CTRI/2011/12/002306
- Lead Sponsor
- Smt Kashibai Navale Medical College and Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other (Terminated)
- Sex
- Not specified
- Target Recruitment
- 60
Age between 30 to 70 years
Sex: Male or Non-lactating female
HbA1 more than 8
Type 2 Diabetic patient on Sulphonylureas or Metformin not responding adequately
Age less than 30 yrs.
Pregnancy
Lactating mother
Patient with Insulin dependent Diabetes Mellites
Patient who is taking oral antidiabetic drugs other than Sulphonyureas and Metformin
Severe and Complicated diabetes
Patient with IHD
Patients having renal or hepatic dysfunction
Patient of Parkinsonism, syncopal migraine
Patient who is taking Salicylates, Sulfonamides, Chloramphenicol, Probenecid, Phenithiazines, Butyrophenones, Thioxanthenes,Metoclopramide
Strong Inhibitors/Inducers/ Substrates of CYP 3A4
Inhibitors -sodium valproate, erythromycin, Fluroquinolones except ofloxacin, verapamil, diltiazem, propoxyphene, allopurinol, MAO inhibitors, disulfiram, tolbutamide, metronidazole,captopril, enalpril, carbidopa
Inducers :Phenobarbitone, phenytoin, carbamazepine, ethanol, clofibrate, griseofulvin, Rifampcin, pyridoxine
Substrates: barbiturates, warfarin,theophylline, paracetamol, ascorbic acid, dextropropoxyphene, tolbutamide, diazepam, vit D, oral contraceptives, antidepressants, quinidine, terfanidine,phenytion, carbamazepine, morphine, pethidine,
HIV positive patients
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method